THERAPY AND LONG-TERM RESULTS OF HEPATITIS C-ASSOCIATED INDOLENT NON-HODGKIN LYMPHOMA
(Abstract release date: 05/19/16)
EHA Library. lepkov s. 06/09/16; 134773; PB1873
Dr. sergey lepkov
Contributions
Contributions
Abstract
Abstract: PB1873
Type: Publication Only
Background
The incidence of chronic hepatitis C (HCV) in patients with indolent B-cell non-Hodgkin's lymphoma (IL) is approximately 15%. In those cases where the tumor cell NHL patients were in the presence of hepatitis C virus protein by immunohistochemistry (IHC), we define diagnosis of hepatitis C associated indolent lymphoma (IL+C).
Aims
Since 2004 to 2014 81 patients were observed with IL + C. The median age 50 years, the disease is equally common in men and women. Almost all patients (97%) were determined III-IV st of the disease. In 25% of patients were primary extranodal variants IL+C . Most often determined by the follicular lymphoma, 74%, 32% - cell lymphoma marginal zone. HCV RNA was determined in 82% of patients in the blood, the median viral load was 2.3x105 copies / mL . Increased ALT and LDH was diagnosed in 71% and 82%, respectively.
Methods
As a first-line therapy of 52 patients was only antiviral treatment by interferon and ribaverin . If tumor remission was achieved, the antiviral therapy lasted for 2 years.29 patients as a first line therapy was immunochemotherapy (R-CHOP, R-CVP).
Results
Complete and partial remission of antiviral therapy were obtained in 88% of patients, on immunochemotherapy - in 64% of patients.Median progression-free survival in patients with IL + C treated with antiviral treatment was 42 months, during immunochemotherapy - 19 months (p = 0.00001). Five-year overall survival was 67% and 32%, respectively (p = 0.0003).After immunohimoterapy in 19 patients was the relapse of the disease . All this patients was treated by antiviral therapy as second-line therapy . Complete and partial remission was achieved in 92% of patients. Median progression-free survival in these patients was 31 months.
Conclusion
Antiviral therapy in first-line and relapse of disease better then immunochemotherapy in the overall effectiveness, of the disease-free survival and overall survival in patients of NHL associated with hepatitis C. Antiviral therapy is a priority for patients with hepatitis C-associated lymphoma
Session topic: E-poster
Keyword(s): Hepatitis C virus
Type: Publication Only
Background
The incidence of chronic hepatitis C (HCV) in patients with indolent B-cell non-Hodgkin's lymphoma (IL) is approximately 15%. In those cases where the tumor cell NHL patients were in the presence of hepatitis C virus protein by immunohistochemistry (IHC), we define diagnosis of hepatitis C associated indolent lymphoma (IL+C).
Aims
Since 2004 to 2014 81 patients were observed with IL + C. The median age 50 years, the disease is equally common in men and women. Almost all patients (97%) were determined III-IV st of the disease. In 25% of patients were primary extranodal variants IL+C . Most often determined by the follicular lymphoma, 74%, 32% - cell lymphoma marginal zone. HCV RNA was determined in 82% of patients in the blood, the median viral load was 2.3x105 copies / mL . Increased ALT and LDH was diagnosed in 71% and 82%, respectively.
Methods
As a first-line therapy of 52 patients was only antiviral treatment by interferon and ribaverin . If tumor remission was achieved, the antiviral therapy lasted for 2 years.29 patients as a first line therapy was immunochemotherapy (R-CHOP, R-CVP).
Results
Complete and partial remission of antiviral therapy were obtained in 88% of patients, on immunochemotherapy - in 64% of patients.Median progression-free survival in patients with IL + C treated with antiviral treatment was 42 months, during immunochemotherapy - 19 months (p = 0.00001). Five-year overall survival was 67% and 32%, respectively (p = 0.0003).After immunohimoterapy in 19 patients was the relapse of the disease . All this patients was treated by antiviral therapy as second-line therapy . Complete and partial remission was achieved in 92% of patients. Median progression-free survival in these patients was 31 months.
Conclusion
Antiviral therapy in first-line and relapse of disease better then immunochemotherapy in the overall effectiveness, of the disease-free survival and overall survival in patients of NHL associated with hepatitis C. Antiviral therapy is a priority for patients with hepatitis C-associated lymphoma
Session topic: E-poster
Keyword(s): Hepatitis C virus
Abstract: PB1873
Type: Publication Only
Background
The incidence of chronic hepatitis C (HCV) in patients with indolent B-cell non-Hodgkin's lymphoma (IL) is approximately 15%. In those cases where the tumor cell NHL patients were in the presence of hepatitis C virus protein by immunohistochemistry (IHC), we define diagnosis of hepatitis C associated indolent lymphoma (IL+C).
Aims
Since 2004 to 2014 81 patients were observed with IL + C. The median age 50 years, the disease is equally common in men and women. Almost all patients (97%) were determined III-IV st of the disease. In 25% of patients were primary extranodal variants IL+C . Most often determined by the follicular lymphoma, 74%, 32% - cell lymphoma marginal zone. HCV RNA was determined in 82% of patients in the blood, the median viral load was 2.3x105 copies / mL . Increased ALT and LDH was diagnosed in 71% and 82%, respectively.
Methods
As a first-line therapy of 52 patients was only antiviral treatment by interferon and ribaverin . If tumor remission was achieved, the antiviral therapy lasted for 2 years.29 patients as a first line therapy was immunochemotherapy (R-CHOP, R-CVP).
Results
Complete and partial remission of antiviral therapy were obtained in 88% of patients, on immunochemotherapy - in 64% of patients.Median progression-free survival in patients with IL + C treated with antiviral treatment was 42 months, during immunochemotherapy - 19 months (p = 0.00001). Five-year overall survival was 67% and 32%, respectively (p = 0.0003).After immunohimoterapy in 19 patients was the relapse of the disease . All this patients was treated by antiviral therapy as second-line therapy . Complete and partial remission was achieved in 92% of patients. Median progression-free survival in these patients was 31 months.
Conclusion
Antiviral therapy in first-line and relapse of disease better then immunochemotherapy in the overall effectiveness, of the disease-free survival and overall survival in patients of NHL associated with hepatitis C. Antiviral therapy is a priority for patients with hepatitis C-associated lymphoma
Session topic: E-poster
Keyword(s): Hepatitis C virus
Type: Publication Only
Background
The incidence of chronic hepatitis C (HCV) in patients with indolent B-cell non-Hodgkin's lymphoma (IL) is approximately 15%. In those cases where the tumor cell NHL patients were in the presence of hepatitis C virus protein by immunohistochemistry (IHC), we define diagnosis of hepatitis C associated indolent lymphoma (IL+C).
Aims
Since 2004 to 2014 81 patients were observed with IL + C. The median age 50 years, the disease is equally common in men and women. Almost all patients (97%) were determined III-IV st of the disease. In 25% of patients were primary extranodal variants IL+C . Most often determined by the follicular lymphoma, 74%, 32% - cell lymphoma marginal zone. HCV RNA was determined in 82% of patients in the blood, the median viral load was 2.3x105 copies / mL . Increased ALT and LDH was diagnosed in 71% and 82%, respectively.
Methods
As a first-line therapy of 52 patients was only antiviral treatment by interferon and ribaverin . If tumor remission was achieved, the antiviral therapy lasted for 2 years.29 patients as a first line therapy was immunochemotherapy (R-CHOP, R-CVP).
Results
Complete and partial remission of antiviral therapy were obtained in 88% of patients, on immunochemotherapy - in 64% of patients.Median progression-free survival in patients with IL + C treated with antiviral treatment was 42 months, during immunochemotherapy - 19 months (p = 0.00001). Five-year overall survival was 67% and 32%, respectively (p = 0.0003).After immunohimoterapy in 19 patients was the relapse of the disease . All this patients was treated by antiviral therapy as second-line therapy . Complete and partial remission was achieved in 92% of patients. Median progression-free survival in these patients was 31 months.
Conclusion
Antiviral therapy in first-line and relapse of disease better then immunochemotherapy in the overall effectiveness, of the disease-free survival and overall survival in patients of NHL associated with hepatitis C. Antiviral therapy is a priority for patients with hepatitis C-associated lymphoma
Session topic: E-poster
Keyword(s): Hepatitis C virus
{{ help_message }}
{{filter}}